| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/12/2005 | US20050101576 Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| 05/12/2005 | US20050101571 Methods of treating cancer using a combination of drugs |
| 05/12/2005 | US20050101565 Using mixture containing pantethine |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101562 Lipase inhibiting composition |
| 05/12/2005 | US20050101561 HDL-boosting combination therapy complexes |
| 05/12/2005 | US20050101557 Immunostimulatory nucleic acid molecules |
| 05/12/2005 | US20050101554 Methods for treating and preventing infectious disease |
| 05/12/2005 | US20050101544 Such as montelukast, zafirlukast or pranlukast; low amounts of active agents, less prone to detrimental side effects |
| 05/12/2005 | US20050101542 Combination therapy for controlling appetites |
| 05/12/2005 | US20050101540 STAT modulators |
| 05/12/2005 | US20050101537 Use of exendins and agonists thereof for lowering plasma lipid |
| 05/12/2005 | US20050101536 Modulation of angiogenesis |
| 05/12/2005 | US20050101530 Cellular virus receptors and methods of use |
| 05/12/2005 | US20050101529 Protein modification and maintenance molecules |
| 05/12/2005 | US20050101522 Antihyperplastic agents; antitumor agents; side effect reduction |
| 05/12/2005 | US20050101004 Screening for a compound to inhibit the urge for urinary incontinence by detecting activation of KCNQ protein in the host cell; measuring the membrane potential of the host cell and selecting the compound whose presence causes hyperpolarization in themembrane potential of the host cell |
| 05/12/2005 | US20050100918 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100917 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100891 Identifying modulators which control endothelial cell and viral gene expression; diagnosis and treatment of cell proliferative disorders; viricides; anticancer agents |
| 05/12/2005 | US20050100617 Method for improving age-related physiological deficits and increasing longevity |
| 05/12/2005 | US20050100614 Chromium bound to niacin and three compounds from the group consisting of (-) hydroxycitric acid, zinc (particularly zinc methionine), trans-reseveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek. |
| 05/12/2005 | US20050100612 Virucidal activities of cetylpyridinium chloride |
| 05/12/2005 | US20050100611 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors |
| 05/12/2005 | US20050100610 Use of bioactive fraction from cow urine distillate ('Go-mutra'} as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 05/12/2005 | US20050100601 Virucidal activities of cetylpyridinium chloride |
| 05/12/2005 | US20050100594 Tizanidine and valdecoxib for example; muscle relaxant is released in an extended release manner and a cyclooxygenase-2 inhibitor in immediate release form; treating pain, spasticity |
| 05/12/2005 | US20050100547 Also a method for detecting an agent capable of binding TRAF2 binding site of sphingosine kinase by contacting cells with a putative agent and detecting an altered expression phenotype |
| 05/12/2005 | US20050100537 Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
| 05/12/2005 | US20050100530 Medicinal composition |
| 05/12/2005 | US20050100529 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and anti-cancer agent, antibiotic, anti-inflammatory agent, steroid, cytokine, immunosuppressive agent |
| 05/12/2005 | US20050098502 filtration of coal tar to remove impurities, then adding zinc pyrithione, surfactants and carriers to form mixtures used for the treatment of skin disorders |
| 05/12/2005 | CA2544763A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 05/12/2005 | CA2544255A1 Water-soluble compound |
| 05/12/2005 | CA2544100A1 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 05/12/2005 | CA2543745A1 Methods of organ regeneration |
| 05/12/2005 | CA2543696A1 Combinations for hcv treatment |
| 05/12/2005 | CA2543685A1 Neutrophil activation by immune response modifier compounds |
| 05/12/2005 | CA2543255A1 Methods and compositions for regenerating connective tissue |
| 05/12/2005 | CA2543252A1 Use of bh4 for the treatment of respiratory diseases |
| 05/12/2005 | CA2543187A1 Medicamentously targeted local lipolysis |
| 05/12/2005 | CA2542968A1 Zeolite molecular sieves for the removal of toxins |
| 05/12/2005 | CA2542884A1 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent |
| 05/12/2005 | CA2542752A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof |
| 05/12/2005 | CA2542277A1 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith |
| 05/11/2005 | EP1529529A1 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for immunomodulation, immunostimulation and/or antiphlogistic treatment |
| 05/11/2005 | EP1529527A2 Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 05/11/2005 | EP1529116A1 Methods for the treatment of dementia based on apo e genotype |
| 05/11/2005 | EP1529062A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 05/11/2005 | EP1529058A2 A non-selective cation channel in neural cells and methods for treating brain swelling |
| 05/11/2005 | EP1529054A2 Therapeutic protein and treatments |
| 05/11/2005 | EP1529038A1 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 05/11/2005 | EP1528923A1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris |
| 05/11/2005 | EP1528894A2 Biomatrix structural containment and fixation systems and methods of use thereof |
| 05/11/2005 | EP1289522B1 Medicaments for the adjuvant therapy of dementia comprising alpha lipoic acid |
| 05/11/2005 | EP1280531A4 Local anesthetic methods and kits |
| 05/11/2005 | EP1259126B1 Strengthening natural healing drink |
| 05/11/2005 | EP1257526B1 Aniline-derived ligands for the thyroid receptor |
| 05/11/2005 | EP1248802B9 Soluble ctla4 mutant molecules and uses thereof |
| 05/11/2005 | EP1165541B1 Dimeric compounds and as inhibitors of neuraminidase |
| 05/11/2005 | EP1105738B1 Assays for modulating nuclear localisation |
| 05/11/2005 | EP1100771B1 Compounds and compositions for delivering active agents |
| 05/11/2005 | EP1088069B1 Angiostatin-binding protein |
| 05/11/2005 | EP1084711B1 Remedies for the treatment of itching containing pgd2 antagonists |
| 05/11/2005 | EP1083931B1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 05/11/2005 | EP1068224B1 Pharmaceuticals for the imaging of angiogenic disorders |
| 05/11/2005 | EP1059930B1 Compositions comprising isovaleramide and ibuprofen |
| 05/11/2005 | EP1019072B1 Method for assisting in differential diagnosis and treatment of autistic syndromes |
| 05/11/2005 | EP1005337B1 Pharmacologic drug combination in vagal-induced asystole |
| 05/11/2005 | EP1001771B1 A medicament against endometriosis-associated infertility |
| 05/11/2005 | EP0987943B1 Detecting and treating cancer |
| 05/11/2005 | EP0730606B1 Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR |
| 05/11/2005 | CN1615440A Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3 |
| 05/11/2005 | CN1615439A Genes encoding g-protein coupled receptors and methods of use therefor |
| 05/11/2005 | CN1615368A Effectors of innate immunity |
| 05/11/2005 | CN1615357A Process for the manufacture of human mononuclear phagocytic leukocytes |
| 05/11/2005 | CN1615306A C-5 modified indazolylpyrrolotriazines |
| 05/11/2005 | CN1615297A Phenoxy piperidines for treating diseases such as schizophrenia and depression |
| 05/11/2005 | CN1615155A Anti-proliferative composition |
| 05/11/2005 | CN1615153A Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 05/11/2005 | CN1615152A Method for reducing acne or improving skin tone |
| 05/11/2005 | CN1615150A Assay for the detection of factors that modulate the expression of INGAP |
| 05/11/2005 | CN1615147A Treatment of glioblastoma with thymosin-alpha 1 |
| 05/11/2005 | CN1615144A A composition for treating neurocerebrovascular disorders |
| 05/11/2005 | CN1615139A 25-hydroxy vitamin D3 compositions |
| 05/11/2005 | CN1615137A Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 05/11/2005 | CN1615136A Combinations comprising epothilones and anti-metabolites |
| 05/11/2005 | CN1615134A Pharmaceutical compositions comprising valsartan and NEP inhibitors |
| 05/11/2005 | CN1615128A Preparation for improving the action of receptors |
| 05/11/2005 | CN1615127A Substituted bicyclo[3.3.1]nonan-2, 4, 9-triones as pharmaceutical active ingredients |
| 05/11/2005 | CN1615123A Bilayer pharmaceutical tablets comprising telmisartan and diuretic and their preparation |
| 05/11/2005 | CN1615122A Pharmaceutical formulation comprising bicalutamide |
| 05/11/2005 | CN1201005C Antigen binding fragments that specifically detect cancer cells, nucleotindes encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/11/2005 | CN1200734C Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 05/11/2005 | CN1200733C Reversal of viral-induced systemic shock and respiratory distress by blockade of lymphotoxin beta pathway |
| 05/11/2005 | CN1200726C Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/11/2005 | CN1200714C Use of diterpenoid triepoxides as anti-proliferative agent |
| 05/11/2005 | CN1200707C New use of taxoid derivatives |
| 05/11/2005 | CN1200706C Compositions and methods for treating or preventing inflammatory diseases |
| 05/11/2005 | CN1200702C Use of NMDA antagonist for treatment of irritable bowel syndrome |